Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 10/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19656711 | 0.93 | CFTR (0.54) | CFTRHTR2APDE4DSCN5AKDM4E | |
| SCHEMBL19651573 | 0.85 | CFTR (0.62) | CFTRHTR2APDE4DSCN5AKDM4E | |
| SCHEMBL19656761 | 0.82 | CFTR (0.54) | CFTRHTR2APDE4DSCN5ATSHR | |
| SCHEMBL17793951 | 0.82 | CFTR (0.54) | CFTRHTR2APDE4DSCN5A | |
| SCHEMBL19651529 | 0.77 | CFTR (0.34) | CFTRHTR2APDE4DSCN5AGRIN1 | |
| SCHEMBL19656691 | 0.77 | CFTR (0.47) | CFTRHTR2APDE4DSCN5A | |
| SCHEMBL17793903 | 0.77 | CFTR (0.48) | CFTRHTR2APDE4DSCN5A | |
| SCHEMBL29592296 | 0.71 | CFTR (0.59) | CFTRHTR2APDE4DSCN5ATSHR | |
| SCHEMBL19412365 | 0.71 | CFTR (0.59) | CFTRHTR2APDE4DSCN5ATSHR | |
| SCHEMBL19651539 | 0.70 | KDM4E (0.40) | KDM4ETSHRHSD17B10LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CATABASIS PHARMACEUTICALS, INC. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CPT2, FABP1, ACAA2 | CFTR 182/4885HTR2A 2500/4885PDE4D 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.